Active substances
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| SYMTUZA | 150MG;800MG;200MG;EQ 10MG BASE | tablet · oral | JANSSEN PRODS | Prescription | 17 Jul 2018 |
Symtuza is indicated for the treatment of human immunodeficiency virus type 1 (HIV 1) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg). Genotypic testing should guide the use of Symtuza.
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| SYMTUZA | 02473720 | 10 MG; 150 MG; 800 MG; 200 MG | TABLET · ORAL | JANSSEN INC |
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | SYMTUZA 800-150-200-10 MG TAB | $152.86728 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.